Skip to main content

Dr. Alex Adjei Delivered CURE Distinguished Scholars Seminar on Thursday, June 13

, by CRCHD Staff

Did you miss Dr. Alex Adjei presenting this CURE Distinguished Scholars Seminar? Learn more from this coverage.

The NCI Center to Reduce Cancer Health Disparities was pleased to welcome Alex A. Adjei, MD, PhD, as the featured speaker for a Continuing Umbrella of Research Experiences (CURE) Distinguished Scholars Seminar (DSS). The title of Dr. Adjei’s talk was “Successes and Challenges in Early Phase Drug Development for Cancer Therapy."

A former CURE scholar, Dr. Adjei was the recipient of one of the first CURE K01 awards in 1997.

Today, Dr. Adjei is Professor of Oncology and Pharmacology in the Mayo College of Medicine. He is also a consultant in medical oncology at the Mayo Clinic and Director of the Early Cancer Therapeutics Program across all three Mayo sites.

A distinguished national leader in translational research, drug development and thoracic oncology, Dr. Adjei has spent more than 30 years focused on evaluating mechanisms of drug action and synergistic drug combinations, and applied his expertise in cancer pharmacology, pharmacogenomics and drug development on advancing the treatment of lung cancer.

Dr. Adjei has conducted numerous first-in-human studies of novel anti-cancer agents which have significantly contributed to our understanding of their mechanisms of action and potential efficacy. He received the first ASCO Drug Development Research Professorship in 2012-2017 and is currently editor-in-chief of the Journal of Thoracic Oncology.

The CURE DSS was launched in 2017 as part of the 21 Years of the CURE Program celebration and recognizes outstanding former CURE scholars and their research. These scientific seminars highlight leading-edge cancer research, along with new advancements, ideas and trends in the field of cancer and cancer disparities.

The CURE Program supports individuals from underrepresented groups across the academic continuum—beginning with high school students and continuing through independent cancer researchers—through a pipeline of research funding opportunities. Learn more about CURE.  

< Older Post

National Minority Health Month Spotlight: Paula Aristizabal, MD, MAS

Newer Post >

CRCHD Scholars Demonstrate Breadth of Cancer Research in Professional Development Workshop Flash Talks

Archive